KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cigna (CI) Cash & Equivalents (2017 - 2025)

Cigna's Cash & Equivalents history spans 9 years, with the latest figure at $7.7 billion for Q4 2025.

  • For Q4 2025, Cash & Equivalents rose 1.67% year-over-year to $7.7 billion; the TTM value through Dec 2025 reached $7.7 billion, up 1.67%, while the annual FY2025 figure was $7.7 billion, 1.67% up from the prior year.
  • Cash & Equivalents for Q4 2025 was $7.7 billion at Cigna, up from $6.0 billion in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $9.6 billion in Q2 2023 and bottomed at $3.5 billion in Q3 2021.
  • The 5-year median for Cash & Equivalents is $6.6 billion (2021), against an average of $6.5 billion.
  • The largest annual shift saw Cash & Equivalents crashed 50.1% in 2021 before it soared 116.81% in 2023.
  • A 5-year view of Cash & Equivalents shows it stood at $5.1 billion in 2021, then increased by 16.59% to $5.9 billion in 2022, then soared by 32.04% to $7.8 billion in 2023, then decreased by 3.48% to $7.6 billion in 2024, then increased by 1.67% to $7.7 billion in 2025.
  • Per Business Quant, the three most recent readings for CI's Cash & Equivalents are $7.7 billion (Q4 2025), $6.0 billion (Q3 2025), and $4.3 billion (Q2 2025).